TIDMDDDD
4d Pharma PLC
18 December 2020
4D pharma Joins Landmark Parkinson's Progression Markers
Initiative
A landmark study sponsored by The Michael J. Fox Foundation to
better understand Parkinson's disease and accelerate the
development of new treatments
4D pharma will play an important role as PPMI considers the
microbiome as an area of focus
Leeds, UK, December l8, 2020 , - 4D pharma plc (AIM: DDDD), a
pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs) - a novel class of drug derived from
the microbiome, today announces that it has joined the Parkinson's
Progression Markers Initiative (PPMI) as an industry partner. PPMI
is a landmark study sponsored by The Michael J. Fox Foundation to
better understand Parkinson's disease and accelerate the
development of new treatments.
4D pharma representatives will contribute to the efforts of the
PPMI by joining the Partner Scientific Advisory Board closely
involved in the design and execution of the study. In addition, 4D
pharma will also join a variety of PPMI Working Groups that provide
a forum to discuss PPMI data and address Parkinson's clinical trial
challenges with other PPMI industry and non-profit partners.
"The Michael J. Fox Foundation has made considerable
contributions to the development of therapeutic solutions for the
millions of people with Parkinson's disease. Joining the PPMI
Scientific Advisory Board will enable 4D pharma to bring its
leading expertise in Live Biotherapeutics and the gut-brain axis to
the pioneering joint effort that is the PPMI", said Alex Stevenson,
Chief Scientific Officer, 4D pharma. "This is an excellent forum in
which to share our knowledge and scientific approach and to help
shape the future of high-quality research into Parkinson's disease
and other neurodegenerative conditions, while continuing to learn
from leading experts in the field across industry, academia and
non-profit organisations. 4D pharma will play an important role as
PPMI considers the microbiome as an area of focus, following a
growing body of evidence pointing to the gut microbiome as a new
frontier in our understanding and treatment of Parkinson's
disease."
"We are pleased to welcome 4D pharma as a partner on the
Parkinson's Progression Markers Initiative. It is only with diverse
expertise on the various aspects of this complex disease that we
will better understand it and find solutions for patients," said
MJFF Deputy CEO, Sohini Chowdhury. "There is a significant and
growing interest in the field in understanding the role of the
microbiome in Parkinson's disease and opportunities for therapeutic
intervention. 4D pharma brings expertise in this novel area of
research to our Scientific Advisory Board, and we look forward to
their insights and contributions."
In addition to its contribution to PPMI, 4D pharma continues to
make progress with regards to its own pipeline of Live
Biotherapeutic candidates for Parkinson's disease. 4D pharma has
previously published pre-clinical data demonstrating the
neuroprotective effects of Live Biotherapeutics in an animal model
of Parkinson's disease, and work investigating the mechanisms of
these therapeutic effects. The Company continues to make progress
in the planning and design of a first-in-human clinical trial in
Parkinson's disease patients; this would be the first clinical
trial of a Live Biotherapeutic in the treatment of Parkinson's.
About the Parkinson's Progression Markers Initiative
PPMI is a landmark observational longitudinal clinical study
launched by MJFF in 2010 to help identify, develop, and validate
biomarkers of Parkinson's disease progression to further the
development of disease-modifying therapies. PPMI is funded by MJFF
and a consortium of key industry players, non-profit organizations
and private individuals, and involves active participation of
stakeholders from government, the biopharmaceutical industry and
academia to collectively design, implement and fund this
comprehensive and pioneering research program.
PPMI collects and analyses a suite of clinical, imaging and
biological data over time to measure and track disease risk, onset
and progression, to establish new biomarkers for use in clinical
trials of disease-modifying therapies. The study is building on its
33 clinical sites and 1,400 enrolled volunteers, with plans to grow
to more than 50 clinical sites in 13 countries and more than 4,000
participants.
For more information and to see 4D pharma's PPMI consortium
peers visit
https://www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors/
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx(R), that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programmes,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumours, a Phase I
study of MRx0518 in patients with pancreatic cancer, a Phase I/II
study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in
patients hospitalised with COVID-19, and Blautix(R) in Irritable
Bowel Syndrome (IBS) which has completed a successful Phase II
trial. Preclinical-stage programmes include candidates for CNS
disease such as Parkinson's disease and other neurodegenerative
conditions. The Company has a research collaboration with MSD, a
tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to
discover and develop Live Biotherapeutics for vaccines.
In October 2020 4D pharma announced its intention to merge with
Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose
acquisition company (SPAC), and seek a NASDAQ listing. The merger
is expected to be completed and the NASDAQ listing of 4D pharma
American Depositary Shares (ADSs) under the ticker symbol 'LBPS' is
currently expected to become effective in early 2021, subject to
approval of 4D Shareholders and Longevity Shareholders, and the SEC
review process.
For more information, refer to https://www.4dpharmaplc.com .
Contact Information:
4D Pharma
Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130
Investor Relations: ir@4dpharmaplc.com
Investor Relations
Julie Seidel, Stern Investor Relations, Inc. +1-212-362-1200
Julie.seidel@sternir.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
3000
Philip Davies / Justin McKeegan / Iqra Amin (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson / Phil Walker
Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKKFBBFBDKDBD
(END) Dow Jones Newswires
December 18, 2020 03:53 ET (08:53 GMT)
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Apr 2023 a Apr 2024